Search

Jason M Foulks

from Sandy, UT
Age ~44
Get Report
Also known as:
Jason Marc Foulks
Phone and address:
11352 S Clifford Cir, Sandy, UT 84092
Related to:
Amy B Foulks, 47Randy K Johnson, 70Cheryl M Carrigan, 70Matthew N Foulks, 47Jodi A Rhodehouse, 49Lacy R Foulks, 43Kathryn A Foulks, 71Foulks B Foulks, 47
Connected to:
Andrew B Foulks, 33Brittney N Foulks, 34Christine M Foulks, 72Liliana Foulks, 46Meighann Foulks, 36Michel Foulks, 56Shawn K Foulks, 52Todd E Foulks, 52Mark Foulon, 67Nicolas Foulon, 40

Jason Foulks Phones & Addresses

    s
  • 11352 S Clifford Cir, Sandy, UT 84092
  • 951 E Avila Ct, Sandy, UT 84094
  • 294 Beverlee Ann Dr, Draper, UT 84020 (801) 352-2876
  • 110 Cyprus St, Bingham Canyon, UT 84006 (801) 352-2876
  • Copperton, UT
  • 1985 2100, Salt Lake City, UT 84108 (801) 583-8695
  • 1920 2990, Salt Lake City, UT 84106 (801) 583-8695
  • 6188 Vine Hill Ln, Salt Lake City, UT 84121 (801) 266-0898

Work

Position: Homemaker

Education

Degree: High school graduate or higher

Resumes

Resumes

Jason Foulks Photo 1

Senior Director, Preclinical Research

View page
Location:
951 east Avila Ct, Sandy, UT 84094
Industry:
Biotechnology
Work:
Sumitomo Dainippon Pharma Oncology
Senior Director, Preclinical Research
Tolero Pharmaceuticals, Inc.
Director, Preclinical Development
Great Basin Scientific Jan 2017 - May 2017
Director, Product Transfer, Research and Development
Great Basin Scientific Aug 1, 2014 - Jan 2017
Associate Director, Research and Development at Great Basin Corporation
Allocure Feb 2014 - Jun 2014
Director, Translational Biology
Education:
University of Utah 2001 - 2007
Doctorates, Doctor of Philosophy University of Utah 1998 - 2001
Bachelors, Bachelor of Science, Biology
Skills:
Assay Development
Biotechnology
Cell Biology
Drug Discovery
Molecular Biology
Drug Development
Biochemistry
Pharmacology
Biomarker Discovery
Cancer
Microbiology
Oncology
Cell Culture
Cancer Research
Life Sciences
Lifesciences
Translational Research
High Throughput Screening
Flow Cytometry
Cell
Pharmaceutical Industry
Jason Foulks Photo 2

Jason Foulks

View page

Publications

Us Patents

Axl Kinase Inhibitors And Use Of The Same

View page
US Patent:
20210205304, Jul 8, 2021
Filed:
Nov 9, 2020
Appl. No.:
17/092521
Inventors:
- Cambridge MA, US
Steven L. Warner - Sandy UT, US
Paul Flynn - Citrus Heights CA, US
David J. Bearss - Alpine UT, US
Jason Marc Foulks - Sandy UT, US
Nozomi Tomimatsu - Osaka, JP
Ken Fujimura - Osaka, JP
Hiroki Umehara - Osaka, JP
Akihito Nonoyama - Hyogo, JP
Akihito Kiguchiya - Nara, JP
Assignee:
Sumitomo Dainippon Pharma Oncology, Inc. - Cambridge MA
International Classification:
A61K 31/506
A61P 35/02
A61K 31/519
C07D 403/12
Abstract:
Tartrate salts of the compound of structure (I),(I), crystalline forms thereof, and therapeutic applications thereof for treating solid tumors (e.g., advanced solid tumor) or hematopoietic cancers. Also provided herein are methods for synthesizing the tartrate salts and the crystalline forms thereof.

Materials And Methods For Treating Cancer

View page
US Patent:
20210145830, May 20, 2021
Filed:
Apr 5, 2019
Appl. No.:
17/045411
Inventors:
- Rochester MN, US
- Cambridge MA, US
Steven L. Warner - Sandy UT, US
David J. Bearss - Alpine UT, US
Jason Marc Foulks - Sandy UT, US
Lars Mouritsen - South Jordan UT, US
Clifford J. Whatcott - West Jordan UT, US
International Classification:
A61K 31/506
A61P 35/00
C12N 5/0783
Abstract:
This document provides methods for determining biological age of mammalian subjects or assessing whether the subjects are aging normally. Also provided herein are methods for determining whether therapeutic treatment or other interventions for reversing or slowing down aging are effective. This document also provides methods and materials for slowing the progression of biological aging.

Pkm2 Modulators And Methods For Their Use

View page
US Patent:
20210002233, Jan 7, 2021
Filed:
Jul 15, 2020
Appl. No.:
16/930254
Inventors:
- Cambridge MA, US
Yong XU - Midvale UT, US
Michael David SAUNDERS - Sandy UT, US
Xiaohui LIU - Holladay UT, US
Scott Albert PEARCE - Clearfield UT, US
Kevin Bret WRIGHT - Cottonwood Heights UT, US
Jason Marc FOULKS - Sandy UT, US
Kenneth Mark PARNELL - Kaysville UT, US
Steven Brian KANNER - Salt Lake City UT, US
David Lee VOLLMER - South Jordan UT, US
Jihua LIU - San Marcos CA, US
International Classification:
C07D 231/14
C07D 231/38
C07F 9/6503
C07D 403/12
C07D 401/14
C07D 405/14
C07D 231/16
C07D 401/12
C07D 403/14
C07D 405/12
C07D 409/12
C07D 409/14
C07D 413/12
C07D 417/12
C07D 417/14
A61P 11/00
A61P 43/00
A61P 35/00
A61K 31/4155
Abstract:
Compounds having activity as PKM2 activators are disclosed. The compounds have the following structure (I):including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R, R, R, R, Rand Rare as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Compositions Comprising Pkm2 Modulators And Methods Of Treatment Using The Same

View page
US Patent:
20200297698, Sep 24, 2020
Filed:
Mar 20, 2020
Appl. No.:
16/826131
Inventors:
- Lehi UT, US
David J. BEARSS - Alpine UT, US
Jason Marc FOULKS - Sandy UT, US
International Classification:
A61K 31/4155
C07K 16/28
A61K 35/04
Abstract:
A compound of Structure (I):or a pharmaceutically acceptable salt thereof, alone or in combination with a second therapeutic agent, as well as methods of treating a PKM2-mediated disease or disorder using the same are provided herein.

Pkm2 Modulators And Methods For Their Use

View page
US Patent:
20200109120, Apr 9, 2020
Filed:
Sep 26, 2019
Appl. No.:
16/584912
Inventors:
- Lehi UT, US
Yong XU - Midvale UT, US
Michael David SAUNDERS - Sandy UT, US
Xiaohui LIU - Holladay UT, US
Scott Albert PEARCE - Clearfield UT, US
Kevin Bret WRIGHT - Cottonwood Heights UT, US
Jason Marc FOULKS - Sandy UT, US
Kenneth Mark PARNELL - Kaysville UT, US
Steven Brian KANNER - Salt Lake City UT, US
David Lee VOLLMER - South Jordan UT, US
Jihua LIU - San Marcos CA, US
International Classification:
C07D 231/14
C07D 231/38
C07F 9/6503
C07D 403/12
C07D 401/14
C07D 405/14
C07D 231/16
C07D 401/12
C07D 403/14
C07D 405/12
C07D 409/12
C07D 409/14
C07D 413/12
C07D 417/12
C07D 417/14
Abstract:
Compounds having activity as PKM2 activators are disclosed. The compounds have the following structure (I):including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R, R, R, R, Rand Rare as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Methods For Treating Diseases Associated With Abnormal Acvr1 Expression And Acvr1 Inhibitors For Use In The Same

View page
US Patent:
20200085823, Mar 19, 2020
Filed:
Jul 26, 2019
Appl. No.:
16/523829
Inventors:
- Lehi UT, US
David J. Bearss - Alpine UT, US
Clifford J. Whatcott - West Jordan UT, US
Jason Marc Foulks - Sandy UT, US
Stephen Patrick Anthony - Heber City UT, US
Paul Flynn - Citrus Heights CA, US
Yuji Fujiwara - Draper UT, US
Yuka Arikawa - Minoh-city, JP
International Classification:
A61K 31/506
A61K 9/48
A61K 9/16
A61P 35/00
A61K 9/00
Abstract:
Methods for treating a disease in a subject in need thereof by administering an ACVR1 inhibitor having the following formula (I) are disclosed:including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R, R, R, and Rare as defined herein. Subjects that may benefit from treatment may have mutations in their ACVR1 gene. Various diseases may be treated using the described methods, including cancers (e.g., diffuse intrinsic pontine glioma (DIPG)) and genetic disorders (e.g., fibrodysplasia ossificans progressiva (FOP)).

Pkm2 Modulators And Methods For Their Use

View page
US Patent:
20170015631, Jan 19, 2017
Filed:
Jun 15, 2016
Appl. No.:
15/183581
Inventors:
- Lehi UT, US
Yong Xu - Midvale UT, US
Michael David Saunders - Sandy UT, US
Xiaohui Liu - Holladay UT, US
Scott Albert Pearce - Clearfield UT, US
Kevin Bret Wright - Cottonwood Heights UT, US
Jason Marc Foulks - Draper UT, US
Kenneth Mark Parnell - Kaysville UT, US
Steven Brian Kanner - Salt Lake City UT, US
David Lee Vollmer - South Jordan UT, US
Jihua Liu - San Marcos CA, US
International Classification:
C07D 231/14
C07D 417/12
C07D 405/14
C07D 409/14
C07D 413/12
C07D 401/12
C07D 409/12
C07D 403/12
C07D 405/12
Abstract:
Compounds having activity as PKM2 activators are disclosed. The compounds have the following structure (I):including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R, R, R, R, Rand Rare as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Pkm2 Modulators And Methods For Their Use

View page
US Patent:
20150344436, Dec 3, 2015
Filed:
Oct 16, 2013
Appl. No.:
14/435976
Inventors:
- Lehi UT, US
Yong Xu - Midvale UT, US
Michael David Saunders - Sandy UT, US
Xiaohui Liu - Holladay UT, US
Scott Albert Pearce - Clearfield UT, US
Kevin Bret Wright - Cottonwood Heights UT, US
Jason Marc Foulks - Draper UT, US
Kenneth Mark Parnell - Kaysville UT, US
Steven Brian Kanner - Salt Lake City UT, US
David Lee Vollmer - South Jordan UT, US
Jihua Liu - San Marcos CA, US
International Classification:
C07D 231/14
C07D 403/12
C07D 417/12
C07F 9/6503
C07D 413/12
C07D 401/12
C07D 417/14
C07D 231/38
C07D 405/12
Abstract:
Compounds having activity as PKM2 activators are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Control profile
Jason M Foulks from Sandy, UT, age ~44 Get Report